A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

NCT01698775 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Omarigliptin
DRUG: Placebo to omarigliptin
DRUG: Glipizide
DRUG: Placebo to glipizide
BIOLOGICAL: Insulin

Sponsor

Merck Sharp & Dohme LLC